-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – Rintatolimod in Metastatic Colorectal Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Rintatolimod in Metastatic Colorectal Cancer report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Rintatolimod in Metastatic Colorectal Cancer Drug Details: Ampligen is under development...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – Tazemetostat Hydrobromide in Transitional Cell Carcinoma (Urothelial Cell Carcinoma)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Tazemetostat Hydrobromide in Transitional Cell Carcinoma (Urothelial Cell Carcinoma) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Tazemetostat Hydrobromide in Transitional Cell Carcinoma (Urothelial...
-
Product Insights
Smallpox – Drugs In Development, 2023
Global Markets Direct’s, ‘Smallpox - Drugs In Development, 2023’, provides an overview of the Smallpox pipeline landscape. The report provides comprehensive information on the therapeutics under development for Smallpox, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key...
-
Product Insights
Monkeypox – Drugs In Development, 2023
Global Markets Direct’s, ‘Monkeypox - Drugs In Development, 2023’, provides an overview of the Monkeypox pipeline landscape. The report provides comprehensive information on the therapeutics under development for Monkeypox, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – MRNA-1010 in Seasonal Influenza
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - MRNA-1010 in Seasonal Influenza report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. MRNA-1010 in Seasonal Influenza Drug Details: mRNA-1010 is under development for the...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – AD-218 in Mixed Dyslipidemia
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalDatas proprietary machine learning algorithms developed using over 10 years of historical data.AD-218 in Mixed Dyslipidemia Drug Details:AD-218 is under development for the treatment of hyperlipidemia and mixed...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – mRNA-1030 in Seasonal Influenza
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalDatas proprietary machine learning algorithms developed using over 10 years of historical data.MRNA-1030 in Seasonal Influenza Drug Details:mRNA-1030 is under development for the prevention of seasonal influenza, including...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Tecovirimat in Monkeypox
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Tecovirimat in Monkeypox report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Tecovirimat in Monkeypox Drug Details: Tecovirimat (Tpoxx / ST-246) is an antiviral...
-
Company Insights
Innovation and Patenting activity of SIGA Technologies Inc Q4 2023
GlobalData, the industry analysis specialist, has released its latest company patent databook "Innovation and Patenting activity of SIGA Technologies Inc Q4 2023". The databook highlights patenting activity of the company in terms of growth in filings and grants, regions protected, impact of various themes, sector applicability of technologies protected. It provides contextual analysis of technical peers, their strategy, dominance (Grant share) and their recent activities. This is an on-demand databook that will be delivered upon request. The report will be...
-
Company Profile
SIGA Technologies Inc – Company Profile
SIGA Technologies Inc (SIGA) is a company that provides health security services. The company develops and commercializes solutions for serious unmet medical needs and threats. It offers an antiviral drug to treat smallpox disease. SIGA offers TPOXX products like oral, iv, liquid and post-exposure. The company’s Tecovirimat is combined with smallpox vaccines to prevent disease and reduce vaccine-related complications. It also develops orally administered small molecule therapeutics for the treatment and prevention of diseases caused by viruses. The company provides...
Add to Basket